Pneumococcal 15-Valent Conjugate Vaccine Approved for Pediatric Use
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
Can long-COVID lung diseases be better understood and classified via analysis of abnormalities seen on transbronchial lung cryobiopsies?
What kinds of pulmonary sequelae do patients experience a year after hospitalization with COVID-19 pneumonia — and does the level of ventilatory support matter?
Can nonsevere childhood community-acquired pneumonia be effectively treated by a short course of antibiotics?
The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes.
How does methylprednisolone dose and duration affect rates of VTE and mortality among patients with COVID-19 pneumonia?
The randomized, double-blind, placebo-controlled study included a total of 380 patients aged 6 to 71 months with nonsevere CAP.
The new 10-count packaging provides convenience for patients and health care professionals with a complete 5-day course of treatment.
The update applies to patients who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.
The randomized, double-blind trial enrolled a total of 1796 participants, of which 1727 completed the study.